Literature DB >> 35197325

Association of Clonal Hematopoiesis of Indeterminate Potential with Worse Kidney Function and Anemia in Two Cohorts of Patients with Advanced Chronic Kidney Disease.

Caitlyn Vlasschaert1, Amy J M McNaughton2, Michael Chong3,4,5,6, Elina K Cook2, Wilma Hopman7, Bryan Kestenbaum8, Cassianne Robinson-Cohen9, Jocelyn Garland7, Sarah M Moran7, Guillaume Paré3,4,5,6, Catherine M Clase10,11,12, Mila Tang13, Adeera Levin14, Rachel Holden7, Michael J Rauh2, Matthew B Lanktree3,10,11,12.   

Abstract

BACKGROUND: Clonal hematopoiesis of indeterminate potential (CHIP) is an inflammatory premalignant disorder resulting from acquired genetic mutations in hematopoietic stem cells. This condition is common in aging populations and associated with cardiovascular morbidity and overall mortality, but its role in CKD is unknown.
METHODS: We performed targeted sequencing to detect CHIP mutations in two independent cohorts of 87 and 85 adults with an eGFR<60 ml/min per 1.73m2. We also assessed kidney function, hematologic, and mineral bone disease parameters cross-sectionally at baseline, and collected creatinine measurements over the following 5-year period.
RESULTS: At baseline, CHIP was detected in 18 of 87 (21%) and 25 of 85 (29%) cohort participants. Participants with CHIP were at higher risk of kidney failure, as predicted by the Kidney Failure Risk Equation (KFRE), compared with those without CHIP. Individuals with CHIP manifested a 2.2-fold increased risk of a 50% decline in eGFR or ESKD over 5 years of follow-up (hazard ratio 2.2; 95% confidence interval, 1.2 to 3.8) in a Cox proportional hazard model adjusted for age, sex, and baseline eGFR. The addition of CHIP to 2-year and 5-year calibrated KFRE risk models improved ESKD predictions. Those with CHIP also had lower hemoglobin, higher ferritin, and higher red blood cell mean corpuscular volume versus those without CHIP.
CONCLUSIONS: In this exploratory analysis of individuals with preexisting CKD, CHIP was associated with higher baseline KFRE scores, greater progression of CKD, and anemia. Further research is needed to define the nature of the relationship between CHIP and kidney disease progression.
Copyright © 2022 by the American Society of Nephrology.

Entities:  

Keywords:  anemia; chronic inflammation; chronic renal insufficiency; clonal hematopoiesis; clone cells; cohort studies; hematopoiesis; macrophages

Mesh:

Year:  2022        PMID: 35197325      PMCID: PMC9063886          DOI: 10.1681/ASN.2021060774

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   14.978


  53 in total

1.  Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes.

Authors:  Catherine C Coombs; Ahmet Zehir; Sean M Devlin; Ashwin Kishtagari; Aijazuddin Syed; Philip Jonsson; David M Hyman; David B Solit; Mark E Robson; José Baselga; Maria E Arcila; Marc Ladanyi; Martin S Tallman; Ross L Levine; Michael F Berger
Journal:  Cell Stem Cell       Date:  2017-08-10       Impact factor: 24.633

2.  A predictive model for progression of chronic kidney disease to kidney failure.

Authors:  Navdeep Tangri; Lesley A Stevens; John Griffith; Hocine Tighiouart; Ognjenka Djurdjev; David Naimark; Adeera Levin; Andrew S Levey
Journal:  JAMA       Date:  2011-04-11       Impact factor: 56.272

3.  Age-related clonal hematopoiesis associated with adverse outcomes.

Authors:  Siddhartha Jaiswal; Pierre Fontanillas; Jason Flannick; Alisa Manning; Peter V Grauman; Brenton G Mar; R Coleman Lindsley; Craig H Mermel; Noel Burtt; Alejandro Chavez; John M Higgins; Vladislav Moltchanov; Frank C Kuo; Michael J Kluk; Brian Henderson; Leena Kinnunen; Heikki A Koistinen; Claes Ladenvall; Gad Getz; Adolfo Correa; Benjamin F Banahan; Stacey Gabriel; Sekar Kathiresan; Heather M Stringham; Mark I McCarthy; Michael Boehnke; Jaakko Tuomilehto; Christopher Haiman; Leif Groop; Gil Atzmon; James G Wilson; Donna Neuberg; David Altshuler; Benjamin L Ebert
Journal:  N Engl J Med       Date:  2014-11-26       Impact factor: 91.245

4.  Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence.

Authors:  Giulio Genovese; Anna K Kähler; Robert E Handsaker; Johan Lindberg; Samuel A Rose; Samuel F Bakhoum; Kimberly Chambert; Eran Mick; Benjamin M Neale; Menachem Fromer; Shaun M Purcell; Oscar Svantesson; Mikael Landén; Martin Höglund; Sören Lehmann; Stacey B Gabriel; Jennifer L Moran; Eric S Lander; Patrick F Sullivan; Pamela Sklar; Henrik Grönberg; Christina M Hultman; Steven A McCarroll
Journal:  N Engl J Med       Date:  2014-11-26       Impact factor: 91.245

5.  Body mass index, coronary artery calcification, and kidney function decline in stage 3 to 5 chronic kidney disease patients.

Authors:  Jocelyn S Garland; Rachel M Holden; Wilma M Hopman; Sudeep S Gill; Robert L Nolan; A Ross Morton
Journal:  J Ren Nutr       Date:  2012-04-28       Impact factor: 3.655

6.  CRISPR-Mediated Gene Editing to Assess the Roles of Tet2 and Dnmt3a in Clonal Hematopoiesis and Cardiovascular Disease.

Authors:  Soichi Sano; Kosei Oshima; Ying Wang; Yasufumi Katanasaka; Miho Sano; Kenneth Walsh
Journal:  Circ Res       Date:  2018-05-04       Impact factor: 17.367

7.  Prevalence and associations of coronary artery calcification in patients with stages 3 to 5 CKD without cardiovascular disease.

Authors:  Jocelyn S Garland; Rachel M Holden; Patti A Groome; Miu Lam; Robert L Nolan; A Ross Morton; William Pickett
Journal:  Am J Kidney Dis       Date:  2008-06-17       Impact factor: 8.860

8.  Clonal myelopoiesis promotes adverse outcomes in chronic kidney disease.

Authors:  William J Tapper; Nicholas C P Cross; Ahmed A Z Dawoud; Rodney D Gilbert
Journal:  Leukemia       Date:  2021-08-19       Impact factor: 11.528

9.  Associations of epicardial fat with coronary calcification, insulin resistance, inflammation, and fibroblast growth factor-23 in stage 3-5 chronic kidney disease.

Authors:  Jasmine D Kerr; Rachel M Holden; Alexander R Morton; Robert L Nolan; Wilma M Hopman; Cynthia M Pruss; Jocelyn S Garland
Journal:  BMC Nephrol       Date:  2013-01-26       Impact factor: 2.388

10.  Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults.

Authors:  Andrew L Young; Grant A Challen; Brenda M Birmann; Todd E Druley
Journal:  Nat Commun       Date:  2016-08-22       Impact factor: 14.919

View more
  4 in total

1.  Clonal hematopoiesis is not prevalent in Hutchinson-Gilford progeria syndrome.

Authors:  Miriam Díez-Díez; Marta Amorós-Pérez; Jorge de la Barrera; Enrique Vázquez; Ana Quintas; Domingo A Pascual-Figal; Ana Dopazo; Fátima Sánchez-Cabo; Monica E Kleinman; Leslie B Gordon; Valentín Fuster; Vicente Andrés; José J Fuster
Journal:  Geroscience       Date:  2022-06-25       Impact factor: 7.713

Review 2.  Targeting innate immunity-driven inflammation in CKD and cardiovascular disease.

Authors:  Thimoteus Speer; Stefanie Dimmeler; Stefan J Schunk; Danilo Fliser; Paul M Ridker
Journal:  Nat Rev Nephrol       Date:  2022-09-05       Impact factor: 42.439

3.  Clonal Hematopoiesis and CKD Progression.

Authors:  Abhishek Niroula; Roger Belizaire
Journal:  J Am Soc Nephrol       Date:  2022-04-06       Impact factor: 14.978

Review 4.  Clinical Significance of Clonal Hematopoiesis of Indeterminate Potential in Hematology and Cardiovascular Disease.

Authors:  Gregor Hoermann
Journal:  Diagnostics (Basel)       Date:  2022-07-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.